Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal growth factor receptor gene mutation

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Treatments: Carboplatin; Docetaxel

Criteria

Inclusion Criteria:

• 18-75 years old

• Lung adenocarcinoma patients with epidermal growth factor receptor gene mutation,stage I-IIIB after surgery

• The patients' Eastern Cooperative Oncology Group scores are ≤ 0-2

Exclusion Criteria:

• Mismatch conditions above

• Have used other anti-cancer therapy drug before the trial and may influence the outcome